Literature DB >> 3790165

Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity.

K Horgan, E Cooke, M B Hallett, R E Mansel.   

Abstract

Recent studies have demonstrated tamoxifen inhibition of the enzyme protein kinase C (PKC) in vitro. The aim of this study was to investigate the effects of tamoxifen on PKC function in intact human cells. As PKC activates the neutrophil oxidase mechanism the neutrophil was chosen as an experimental model to assess PKC-tamoxifen interaction in these experiments. Neutrophils from healthy volunteers were separated by centrifugation through Ficoll Hypaque. Two separate parameters of oxidase activation; oxygen consumption and reactive oxygen metabolite production were monitored by a Clark electrode chamber and luminol dependent chemiluminescence respectively. Neutrophil chemiluminescence was markedly stimulated by 4 Phorbol-12 myristate-13 acetate (PMA). This stimulation was inhibited by tamoxifen; IC50 = 6.1 +/- 1.6 microM (means +/- S.E.M.) N = 6. Neutrophil oxygen consumption was similarly stimulated by PMA and inhibited by tamoxifen. The tamoxifen inhibition was not due to cell toxicity as assessment of cell integrity by the exclusion of trypan blue and measurement of intracellular concentrations of ATP showed no significant differences before and after treatment. Tamoxifen also inhibited neutrophil chemiluminescence which was stimulated by oleoyl acetyl glycerol and mezerein excluding interaction with PMA as an explanation of its inhibitory effect. These results are consistent with tamoxifen inhibition of PKC function in intact human cells. This may be central to its antitumour action.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790165     DOI: 10.1016/0006-2952(86)90764-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  33 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  [Regression of retroperitoneal fibrosis by combination therapy with tamoxifen and steroids].

Authors:  J Allendorff; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-07-15

3.  Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-ι activity in vitro.

Authors:  Lei Yang; Xiaopeng Yuan; Jie Wang; Cheng Gu; Haowen Zhang; Jiahua Yu; Fenju Liu
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

Review 4.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

5.  The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro.

Authors:  A Francavilla; L Polimeno; A DiLeo; M Barone; P Ove; M Coetzee; P Eagon; L Makowka; G Ambrosino; V Mazzaferro
Journal:  Hepatology       Date:  1989-04       Impact factor: 17.425

6.  Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors:  Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

7.  Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism.

Authors:  B Budziszewska; L Jaworska-Feil; M Kajta; W Lasoń
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 8.  Neuropsychiatric effects of tamoxifen: Challenges and opportunities.

Authors:  Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck
Journal:  Front Neuroendocrinol       Date:  2020-08-18       Impact factor: 8.606

Review 9.  Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.

Authors:  Rosilla F Bachmann; Robert J Schloesser; Todd D Gould; Husseini K Manji
Journal:  Mol Neurobiol       Date:  2005-10       Impact factor: 5.590

10.  Idiopathic retroperitoneal fibrosis: an unusual cause of low back pain.

Authors:  Petr Nemec; Sylva Rybnickova; Pavel Fabian; Zdenek Fojtik; Miroslav Soucek
Journal:  Clin Rheumatol       Date:  2007-10-11       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.